The updated European LeukemiaNet 2022 guidelines now classify all AML cases with an FLT3–ITD mutation as intermediate risk, regardless of the FLT3–ITD allelic ratio or NPM1 mutation status. This evidence concerns the gene FLT3 and acute myeloid leukemia.